Formosa Pharmaceuticals Receive FDA Approval For Clobetasol Propionate Ophthalmic Suspension 0.05%
Exhibitor: FORMOSA PHARMACEUTICALS , INC
Date: 2024-03-28
Booth No.: N/A
TAIPEI – March 4, 2024 – Taiwan-based Formosa Pharmaceuticals (6838.TWO) and AimMax Therapeutics (United States) announced today that the U.S. Food and Drug Administration (FDA) has approved clobetasol propionate ophthalmic suspension 0.05% (APP13007), for the treatment of post-operative inflammation and pain following ocular surgery.
Utilizing a super potent corticosteroid, Clobetasol propionate ophthalmic suspension 0.05% is derived from Formosa Pharma’s proprietary APNT™ nanoparticle formulation platform. This innovative formulation represents the first FDA-approved ophthalmic clobetasol propionate product and the first new steroid in over 15 years on the ophthalmic market, offering patients a convenient and straightforward dosing regimen (twice daily for 14 days without tapering). Two Phase 3 clinical trials demonstrated rapid and sustained clearance of inflammation and pain relief that was statistically and clinically superior to its matching placebo (p<0.001). This novel eyedrop enters a $1.3 billion dollar market for topical ophthalmic steroids and steroid combinations, driven by an estimated seven million ocular surgeries performed annually in the United States.
“This approval marks Formosa Pharma’s entry into the global marketplace and provides a critical foundation and momentum for continued development, as well as advancement of new endeavors. With immense gratitude, we thank our development colleagues at AimMax Therapeutics for their wisdom and tenacity in guiding the program through to success. Equally, we recognize the tireless efforts of our employees and unwavering support from colleagues in the realization of this corporate milestone,” said Erick Co, President and CEO of Formosa Pharmaceuticals. With FDA approval now secured, we look forward to working with our U.S. commercialization partner, Eyenovia, Inc., to reach ophthalmologists and ocular surgery patients, while in parallel working to expand into additional territories and advance our earlier stage pipeline.”
“We congratulate Formosa Pharma for the achievements and are extremely pleased with the collaborative opportunity to bring this novel and impressive formulation to the market to benefit millions of patients for the ease of use and rapid recovery and regain of visual acuity after ocular surgery” said AimMax Therapeutics’ Founder and Chief Executive Officer, Laurene Wang, Ph.D.
“We believe clobetasol propionate ophthalmic suspension 0.05% will be a very synergistic addition to our commercial product portfolio, and we are honored that Formosa has entrusted Eyenovia with the marketing of this important asset in the United States,” stated Michael Rowe, Chief Executive Officer of Eyenovia. “We are already working diligently toward a robust launch of this differentiated and desirable product mid-year, and we believe that, given its more favorable posology and profile compared to other post-surgical steroid options, it has the potential to capture a significant share of an estimated $1.3 billion annual market opportunity.”
More Exhibitor's Press Release
- INORA Brand Strategy to Drive Revenue Growth INORA PHARMACEUTICAL MACHINERY CO., LTD. / 2024-04-26
- Medical Micro Molding Solutions ANN TONG INDUSTRIAL CO.,LTD / 2024-04-18
- Macrogen becomes the first company in Asia to adopt the next generation of genome sequencing technol MACROGEN, INC. / 2024-04-17
- Macrogen becomes the first company to bring NovaSeq X Plus to Korea, marking its first introduction MACROGEN, INC. / 2024-04-17
- Wendy International LTD. Introduction WENDY INTERNATIONAL LTD / 2024-04-17
- ABLE Biott Disposable Bioreactor MITEKLAB CO., LTD. / 2024-04-10
- Femtika SLE technology permits the microfabrication of complex-shaped microfluidic channels MICROSYS ENGINEERING CO., LTD / 2024-04-03
- Microqubic 2D/3D Microscopes and Modular Imaging Systems MICROSYS ENGINEERING CO., LTD / 2024-04-03
- Yenchen Machinery Started Being Enwave Optronics Exclusive Agent PAT(Process Analytical Technology) YENCHEN MACHINERY CO., LTD. / 2024-04-02
- Yenchen acts as agent of NFA Automatic Tablet & Capsule Inspection Machine YENCHEN MACHINERY CO., LTD. / 2024-04-02
- Amaran Biotech Introduces the First Fully-Automated Robotic Aseptic Filling Line in Taiwan AMARAN BIOTECHNOLOGY, INC. / 2024-04-01
- Videojet Ink Jet Print A&D Metal Detector A&D CHECK WEIGHER X-Ray TAIDEVELOP ID TECH CO., LTD. / 2024-03-30
- Videojet Ink Jet Print A&D Metal Detector A&D CHECK WEIGHER TAIDEVELOP ID TECH CO., LTD. / 2024-03-30
- AND Metal Detector check weigher X-RAY Videojet Ink Jet Print TAIDEVELOP ID TECH CO., LTD. / 2024-03-30
- EHPC-Semiconductors, pharmaceuticals, biotechnology, clean room materials EASTERN HIGH PURITY CONNECTION CO., LTD / 2024-03-29
- Formosa Pharmaceuticals Announces Licensing Agreement With Eyenovia for APP13007 Commercialization FORMOSA PHARMACEUTICALS , INC / 2024-03-28
- Formosa Pharmaceuticals Announces Licensing Agreement With Cristália for APP13007 FORMOSA PHARMACEUTICALS , INC / 2024-03-28
- Old-established brand of Vacuum Emulsifying Mixer in Taiwan - Minoga Industrial Co., Ltd. MINOGA INDUSTRIAL CO., LTD. / 2024-03-27
- National Defense Medical Center 2024 Bio Asia-Taiwan Exhibition Projects NATIONAL DEFENSE MEDICAL CENTER / 2024-03-27
- Introduction of National Defense Medical Center NATIONAL DEFENSE MEDICAL CENTER / 2024-03-27